1,3-Benzodioxolylpentanamine

BDP
Clinical data
Other names	1-(3,4-Methylenedioxyphenyl)-2-aminopentane; 3,4-Methylenedioxy-α-propylphenethylamine; MDPPEA; α-Propyl-1,3-benzodioxole-5-ethanamine; α-Propyl-3,4-methylenedioxyphenethylamine; α-Pr-MDPEA; 2-Amino-1-(3,4-methylenedioxyphenyl)pentane
Identifiers
	IUPAC name 1-(1,3-benzodioxol-5-yl)pentan-2-amine;
CAS Number	220491-69;
PubChem CID	22007048;
ChemSpider	13616549;
Chemical and physical data
Formula	C12H17NO2
Molar mass	207.273 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCC(CC1=CC2=C(C=C1)OCO2)N;
	InChI InChI=1S/C12H17NO2/c1-2-3-10(13)6-9-4-5-11-12(7-9)15-8-14-11/h4-5,7,10H,2-3,6,8,13H2,1H3; Key:BWUFCVGRQFOTOA-UHFFFAOYSA-N;

1,3-Benzodioxolylpentanamine (BDP), also known as K or as 3,4-methylenedioxy-α-propylphenethylamine (MDPPEA), is a drug of the phenethylamine and amphetamine families. It is the parent compound of 1,3-benzodioxolyl-N-methylpentanamine (MBDP; methyl-K) and 1,3-benzodioxolyl-N-ethylpentanamine (EBDP; ethyl-K), as well as of pentylone (βk-MBDP). The drug was synthesized by Alexander Shulgin and described in PiHKAL. In contrast to MBDP and EBDP however, it is not known to have ever been tried by humans. Very little is known about BDP.